Imatinib (STI571): Translational Mastery in Tyrosine Kina...

2025-10-21

This thought-leadership article unites mechanistic dissection and strategic guidance on Imatinib (STI571), a selective protein-tyrosine kinase inhibitor that has transformed cancer biology and signal transduction research. Leveraging new insights from cutting-edge studies on tyrosine kinase signaling and neutrophil extracellular trap (NET) biology, the piece charts a translational roadmap for researchers seeking to unravel tumor growth pathways, model resistance mechanisms, and harness Imatinib within advanced assembloid models. By contextualizing Imatinib’s unique selectivity for PDGF receptor, c-Kit, and Abl kinases—and synthesizing evidence from recent NETosis and vascular toxicity studies—the article delivers actionable recommendations for experimental design and translational application, positioning Imatinib as a cornerstone for the next era of precision cancer research.